**Appendix No. 3 - Number of all pediatric cancer patients - newly diagnosed and relapsed cancer patients treated in the cancer center in 2019.**

|  |  |  |
| --- | --- | --- |
|  | **1** | **2** |
| **Diagnostik Group according to the International Classification of Childhood Cancer (ICCC-3)**  | Number of all cancer patients treated in the center in 2019 | Number of cancer patients newly diagnosed in 2019 |
| I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases |  |  |
| (a) Lymphoid leukemias |  |  |
| (b) Acute myeloid leukemias |  |  |
| (c) - (e) Others |  |  |
| II. Lymphomas and reticuloendothelial neoplasms |  |  |
| (a) Hodgkin lymphomas |  |  |
| (b) Non-Hodgkin lymphomas (except Burkitt lymphoma) |  |  |
| (c) - (e) Others |  |  |
| III. CNS and miscellaneous intracranial and intraspinal neoplasms |  |  |
| (b) Astrocytomas |  |  |
| (c) Intracranial and intraspinal embryonal tumors |  |  |
| (a), (d) - (f) Others |  |  |
| IV. Neuroblastoma and other peripheral nervous cell tumors |  |  |
| (a) Neuroblastoma and ganglioneuroblastoma |  |  |
| (b) Others  |  |  |
| V. Retinoblastoma |  |  |
| VI. Renal tumors |  |  |
| (a) Nephroblastoma and other nonepithelial renal tumors |  |  |
| (b) - (c) Others  |  |  |
| VII. Hepatic tumors |  |  |
| VIII. Malignant bone tumors |  |  |
| (a) Osteosarcomas |  |  |
| (b) - (e) Others |  |  |
| IX. Soft tissue and other extraosseous sarcomas |  |  |
| (a)Rhabdomyosarcomas |  |  |
| (b) - (e) Others  |  |  |
| X. Germ cell tumors, trophoblastic tumors, and neoplasms of gonads |  |  |
| XI. Other malignant epithelial neoplasms and malignant melanomas |  |  |
| XII. Other and unspecified malignant neoplasms |  |  |
| Total |  |  |

**Column 1: Number of all cancer patients treated in the cancer center in 2019.** Reflect the number of patients (in- and outpatients) coming to the cancer center, not the number of visits. A patient is to be counted for the year 2019, if he/she was treated for a principal diagnosis of cancer between 1 January and 31 December 2019. Do not include any patient more than once unless they have been treated for more than one malignancy in 2019. All patients should be counted regardless of whether they have a newly diagnosed cancer or have recurrent disease or newly appeared metastases and were referred to the cancer center for further evaluation and primary or secondary treatment. This category excludes consults (e.g., for service or second opinions), diagnoses at autopsy, and former patients admitted for rehabilitation purposes or treatment of some other conditions. It also excludes patient follow-up activities after treatment is completed.

**Column 2: Number of patients newly diagnosed in the center or elsewhere in 2019, which were treated in the center.** Reflect the number of patients (in- and outpatients) coming to the cancer center, not the number of visits. Generally a patient is to be counted as 'newly diagnosed' for the year 2019, if the incidence date (according to the 'Recommendations for Coding Incidence Date' of the European Network of Cancer Registries - ENCR) was in 2019. Do not include any patient more than once unless he/she had more than one malignancy diagnosed in 2019. Do not include patients with recurrent disease. Definition of 'patients treated in the cancer center': therapy planning and the main part of the therapy take place in the cancer center.

\*Further details regarding the classification of childhood cancer are provided in enclosure 3.